19 research outputs found
Attitudes of Physicians Toward Risk Assessment and Use of Granulocyte-Colony Stimulating Factor (G-Csf) As Primary Prophylaxis (Pp) in Patients (Pts) Receiving Chemotherapy with an Intermediate Risk of Febrile Neutropenia (Fn)
n/
Окончательные результаты рандомизированного исследования III фазы ABCSG-24
(Austrian Breast and Colorectal Cancer Study Group),
в котором изучали эффективность неоадъювантной
терапии пациенток с ранними стадиями рака
молочной железы по схеме эпирубицин +
доцетаксел + капецитабин (EDC) по сравнению
со схемой эпирубицин + доцетаксел (ED), а также
эффективность дополнительного назначения
к этим схемам трастузумаба (Т)
при Her2-положительных опухолях
P307 Capecitabine (C) for triple-negative early breast cance (TNBC): Review of available clinical data
563 Pharmacokinetics of epirubicin and paclitaxel during weekly administration in patients with metastasised breast cancer
903 Capecitabine-monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma
442 Fulvestrant (‘Faslodex’) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer
Preliminary results of a pilot-trial with trastuzumab + weekly epidoxorubicin/docetaxel in the neoadjuvant treatment of primary, operable breast cancer
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: A case series
Background:Data regarding the safety and effectiveness of aromatase inhibitors (AIs) as monotherapy or combined with gonadotropin-releasing hormone (GnRH) analogue in male breast cancer are scarce. Methods: In this retrospective chart review, cases of male breast cancer patients treated with AIs with or without a GnRH analogue were evaluated. Results: Twenty-three men were included into this case series. Aromatase inhibitors in combination with or without a GnRH analogue were given as first-line therapy in 60.9% and as second-line therapy in 39.1% of patients, respectively. All patients had visceral metastases, whereas in five of them bone lesions coexisted. In all cases AIs were tolerated well, and no case of grade 3 and 4 adverse events was reported. A partial response was observed in 26.1% of patients and stable disease in 56.5%. Median overall survival (OS) was 39 months and median progression-free survival (PFS) was 13 months. Regarding OS and PFS, no significant effects of GnRH analogue co-administration or type of AI were noted.Conclusion:Our study shows that AIs with or without GnRH analogues may represent an effective and safe treatment option for hormone-receptor positive, pretreated, metastatic, male breast cancer patients. © 2013 Cancer Research UK. All rights reserved
Prognostic impact of breast cancer subtypes in elderly patients
We aimed to analyse the impact of breast cancer (BC) subtypes on the clinical course of disease with special emphasis on the occurrence of brain metastases (BM) and outcome in an elderly BC population. A total number of 706 patients 65 years receiving treatment for BC from 2007 to 2011 were identified from a BC database. 62 patients diagnosed with DCIS and 73 patients with incomplete datasets were excluded, leaving 571 patients for this analysis. Patient characteristics, biological tumour subtypes, and clinical outcome including overall survival (OS) were obtained by retrospective chart review. 380/571 (66, 5 %) patients aged 6574 years were grouped among the young-old, 182/571 (31.9 %) patients aged 7584 years among the oldold, and 29/571 (5.1 %) patients aged 85 years among the oldest-old. 392/571 (68.8 %) patients presented with luminal BC, 119/571 (20.8 %) with HER2-positive, and 59/571 (10.3 %) with triple-negative BC (TNBC). At 38 months median follow-up, 115/571 (20.1 %) patients presented with distant recurrence. A higher recurrence rate was observed in the HER2-positive subtype (43/119 (36.1 %)), as compared to TNBC (15/59 (25.4 %)) and luminal BC (57/392 (14.5 %); p < 0.001). BM were detected at a significantly higher rate in HER2-positive BC patients (9/119 (7.6 %)), as compared to TNBC (2/59 (3.4 %)) and luminal BC patients (6/392 (1.5 %); p = 0.003). Diagnosis of metastatic disease (HR 7.7; 95 % CI 5.211.4; p < 0.001) as well as development of BM (HR 3.5; 95 % CI 1.96.4; p < 0.001) had a significantly negative impact on OS in a time-dependent covariate cox regression model. In contrast to younger BC patients, outcome in this large cohort of elderly patients suggests that HER2-positive diseasenot TNBCfeatured the most aggressive clinical course with the highest rates of metastatic spread and BM. In-depth analysis regarding a potentially distinct biology of TNBC in elderly is therefore warranted.(VLID)346368